CAMBRIDGE, Mass., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric ...

3 days ago · Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal.

Jan 21, 2025 · Biogen’s offer, at about $469 million, effectively assigns Sage a negative value because the Massachusetts biotech had about $569 million in cash and equivalents at the end of September.

Jan 21, 2025 · Sage Therapeutics last week sued partner Biogen just days after receiving an unsolicited buyout offer from the pharma for nearly $470 million, according to reporting by Bloomberg Law.

Jan 28, 2025 · Biogen – which has a longstanding alliance in place with Sage and co-markets Zurzuvae – offered to buy the approximately 90% of shares in Sage that it doesn't already own for $7.22 apiece ...

Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to work on their shared vision to help women suffering from PPD.

Jan 13, 2025 · Sage Therapeutics has had a rough couple of years, its shares in freefall after regulatory and clinical setbacks. Now, long-time partner and current stakeholder Biogen is offering to buy the embattled biotech for around $469 million, according to a Friday securities filing.. As part of a $ 1.5 billion development deal struck in 2020, Biogen has already made a $650 …

4 days ago · Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is...

CAMBRIDGE Mass. – July 24, 2024 – Sage Therapeutics, Inc. (NASDAQ: Sage) and Biogen Inc. (NASDAQ: BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 (BIIB124) as a potential treatment in essential tremor (ET).

Jan 27, 2025 · Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders'...